Athera Biotechnologies AB, a Karolinska Development AB portfolio company, has transferred rights to the recombinant Annexin A5 to Medirista AB, the original innovator of the project. Medirista AB now holds the patent portfolio along with key preclinical assets. Athera will focus on the development of its lead product candidate, a fully human antibody in atherosclerosis.
Recombinant Annexin A5 is being developed as a potential anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery. Annexin A5 has been shown to beneficially affect remodeling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice.